Work

ADAPT: An ongoing international phase III randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment in advanced renal cell carcinoma (RCC).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.4_suppl.449

Authors: Robert A. Figlin, Christopher G. Wood, ADAPT Study Group

Institutions: Cedars-Sinai Medical Center, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2589218908

Cites:

Cited by: 23

Related to: 10